html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:18852529

Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes.

Journal of endocrinological investigation2008The record ↗

glycine

lowersGlycated haemoglobin (HbA1c)

What moved

1 findingHow to read these marks →

Decreases glycated haemoglobin (HbA1c)
very limited
“A1C levels of patients given glycine were significantly lower after 3 months of treatment than those of the placebo group.”
Study
RCT
Duration
3 months
Dose studied
5 g/d glycine, po tid, for 3 months
Population
Patients with type 2 diabetes, mean age 58.5 years, mean baseline A1C 8%

Study record

Design: randomised controlled trial
Species: human
Population: patients with Type 2 diabetes
Participants: 74
Comparator: placebo
Duration: 91 days
Endpoints measured: 3